Overview

A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-24
Target enrollment:
Participant gender:
Summary
This is a multicentre, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the similarity in efficacy, safety, PK profile, and immunogenicity of HLX17 vs. Keytruda( US- and EU-sourced) in the first-line treatment of advanced non-squamous non-small cell lung cancer.
Phase:
PHASE3
Details
Lead Sponsor:
Shanghai Henlius Biotech